NCT05021991Phase 2Completed

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

Study sponsor: Praxis Precision Medicines

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-02-09Actual

Enrollment · participants133Actual

Source updated2024-03-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Essential Tremor

Treatments or interventions studied

100 mg PRAX-944Drug
60 mg PRAX-944Drug
PlaceboDrug
Flexibly dosed 20 mg to 100 mg PRAX-944Drug

Primary outcomes · main study measures

Read the study measures

measure: Change from baseline to Day 56 on the modified ADL; description: The modified ADL is a composite sum of items 1 to 11 of the TETRAS-ADL subscale and items 6 and 7 on the TETRAS-PS. The impact to each function is rated on a 5-point Likert scale from 0 to 4. Before calculating the total score, a scoring adjustment is applied to each item score. The modified ADL score is calculated as the sum of all 13 items (with scoring adjustments) and ranges from 0 to 42 where larger values represent increased direct tremor impact to activities of daily living.; timeFrame: 56 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history